Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-CD19 DASH CAR T cells

A preparation of autologous T lymphocytes that have been genetically modified and transduced with a gamma-retrovirus vector expressing a second-generation chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD19 DASH CAR-T cells target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in B-cell lineage malignancies.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	autologous anti-CD19 CAR T cells CD19 DASH CAR-T cells CD19 targeted DASH CAR-T cells

autologous anti-CD19 DASH CAR T cells

Search NCI's Drug Dictionary